越狱

富阳集成电路产业基地项目首栋封顶_我的网站

A |     CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。

B |     近日，由杭州富春湾集团负责建设的富政工出〔2024〕31号富阳区集成电路及高端装备产业基地项目传来捷报：项目5#配套办公楼顺利完成主体结构封顶，成为项目首栋封顶的单体建筑。该项目位于灵桥镇，东侧为亭山路、南侧为同登街、北侧为虔礼街、西侧为芯通地块。项目总用地面积4.3万平方米，总建筑面积约11.7万平方米，新建厂房及办公楼5幢。

C | 其中，1号、2号楼为6层生产厂房，3号、4号楼为5层生产厂房，5号楼为8层办公楼以及仓库、垃圾房、高配室等。自2025年7月正式开工以来，杭州富春湾集团始终秉持“安全为先、质量为本、精益求精”的建设理念，全面推行标准化施工管理，全力打造品质过硬的精品产业配套工程。目前，5#配套办公楼主体结构施工已全部收官，项目正式转入二次结构、内外装饰、水电及设备安装等施工新阶段。作为富阳重点产业载体，该项目聚焦集成电路与高端装备，构建涵盖半导体材料、设备、封装测试及研发制造的全产业链制造基地。

D | 建成后将带动产业链上下游协同发展，促进就业、激发区域经济活力，助推科创产业升级。

Current article:http://mdl.feishuozhuangkeqi.cyou/news/20260826_9632.html

Published on:02:37:30